Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole for Sleep Disturbances in MDD
NCT01942733Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Sep 2013
- Primary completion
- Aug 2014
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of brexpiprazole orally disintegrating tablet in major depressive disorder (MDD), sleep disorder, sponsored by Lundbeck. Started Sep 2013; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
major depressive disorder (MDD)sleep disorder
Beyond the preview
Go deeper on NCT01942733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01942733.